期刊文献+

前列腺癌患者联合雄激素阻断治疗中的肝功能异常与处理 被引量:5

Liver dysfunction and the treatment in combined androgen blockade for patients with prostate cancer
原文传递
导出
摘要 目的 探讨前列腺癌联合雄激素阻断治疗中出现的肝功能异常和治疗。 方法  2 3例病理确诊的前列腺癌患者 ,年龄 6 3~ 80岁 ,平均 73岁。均行双侧睾丸切除加氟他胺 2 5 0mg每日 3次 ,治疗后平均 6 .2个月出现肝功能异常。治疗前丙氨酸氨基转移酶 (ALT)为 (37± 7.2 )U/L ,17例ALT升至(6 3.5± 7.5 3)U/L ,无黄疸 ;垂盆草冲剂 1包每日 3次 ,VitC 0 .2g及VitBco 2片每日 2次治疗 ;6例ALT(87.2± 7.34)U/L伴黄疸者 ,停用氟他胺 ,5 %GS 2 5 0ml加肝泰乐 1.2g和 (或 ) 5 %GNS 2 5 0ml加泰特0 .6~ 1.2g静脉点滴每日 1次 ,持续 4周。每周随访肝功能。 结果  17例肝功能轻度损害者经上述治疗 1~ 2个月后 ,肝功能恢复正常 ;6例重症者中 4例ALT和总胆红素均恢复正常 ,2例ALT和黄疸出现好转 ,但未正常。 4例转移性肝癌伴骨转移患者平均生存 2 .1年后死亡。 结论 双侧睾丸切除加氟他胺治疗中应密切监测肝功能 ,可预先保肝治疗。 Objective To evaluate the incidence of liver dysfunction and the relevant treatment in patients with prostate cancer with combined androgen blockade. Methods Twenty three patients (mean age,73 years;range,63-80 years) with histologically confirmed prostate cancer showed liver dysfunction during the course of combined blockade with bilateral orchiectomy and flutamide at a dose of 250 mg,3 times per day.After 6.2 months of therapy, ALT level was increased from pre treatment of (37±7.2)U/L to (63.5±7.53)U/L in 17 patients without jaundice and (87.2±7.34)U/L in 6 patients with jaundice.In the 17 patients without jaundice,herbal medicines were used together with vitamin C and vitamin B complex for 1-2 months (first line therapy).In the 6 severely disordered patients,flutamide was stopped, while glucurolactone at a dose of 1.2 g and (or) TAD of 0.6-1.2 g were administered intravenously per day for 4 weeks (second line therapy).Liver function was monitored every week. Results The 17 patients with mild liver dysfunction recovered after application of first line therapy for 1-2 months.The other 6 patients with relatively severe dysfunction had recovery or improvement with additional second line therapy.Of these patients,4 died of hepatic metastases after 2.1 years. Conclusions It is necessary to monitor liver function during the course of combined androgen blockade and to adopt liver protecting therapy for patients with prostate cancer who previously had hepatitis.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2005年第1期49-50,共2页 Chinese Journal of Urology
关键词 前列腺癌 雄激素 治疗 肝功能异常 Prostatic neoplasms Androgen Orchiectomy Liver function
  • 相关文献

参考文献6

  • 1Fritz HS. Hormonal therapy of prostate cancer. In: Walsh PC, Retik AB,Vaughan ED, et al. eds. Campbell' s Urology. Vol 4.8th ed.Philadelphia: Saunders, 2002.3182 -3218. 被引量:1
  • 2邬祥惠.病毒性肝炎[A]..实用内科学 第11版[C].北京:人民卫生出版社,2001.315. 被引量:4
  • 3Wada T, Ueda MM, Abe K, et al. Risk factor of liver disorders caused by flutamide-statistical analysis using multivariate logistic regression analysis. Hinyokika Kiyo, 1999,45:521-526. 被引量:1
  • 4Pu YS, Liu CM, Kao JH,et al. Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. Eur Urol, 1999,36: 293-297. 被引量:1
  • 5方祖军,丁强,姚孟树,张元芳.前列腺癌患者伴其他器官的原发性恶性肿瘤[J].中华外科杂志,2000,38(7):541-541. 被引量:1
  • 6Kojima M, Kamoi K, Ukimura O, et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study. Int J Urol,2002,9:42 -46. 被引量:1

共引文献3

同被引文献19

  • 1钱伟庆,孙忠全,宋建达.足叶乙甙联合环磷酰胺治疗雄激素抵抗性前列腺癌[J].中华泌尿外科杂志,2005,26(4):267-269. 被引量:2
  • 2张小东,许克新,王晓峰,侯树坤.TURP在前列腺癌诊治中的作用评价[J].中华泌尿外科杂志,2005,26(5):308-311. 被引量:36
  • 3汪清,黄苏溪,罗勇,倪泽称.经尿道前列腺电汽化切除加雄激素阻断治疗晚期前列腺癌[J].现代泌尿外科杂志,2005,10(3):142-144. 被引量:17
  • 4马腾骧.现代泌尿外科学[M].天津:天津科学技术出版社,2000.697-710. 被引量:184
  • 5FRITZ HS.Hormonal therapy of prostate cancer.In: walsh PC,Retik AB,Vaughan ED, et al.eds,Campbell,s urology, vol 4. 8thed.Philadelphia: Saunders, 2002.3182-3218. 被引量:1
  • 6Kojima M, Kamoi K. Ukimura O, et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced.hepatopathy in patients with prostate cancer: a preliminary study,Int'J Urol.2002,9:42-46. 被引量:1
  • 7Fritz HS.Hormonal therapy of prostate cancer[M].In:Walsh PC,Retik AB,Vaughan ED,et al.Campbell's urology.Vol 4.8th ed.Philadelphia:Saunders,2002 ;3182-218. 被引量:1
  • 8Kojima M,Kamoi K,Ukimura O,et al.Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer:a preliminary study[J].Int J Urol,2002 ;9:42-6. 被引量:1
  • 9Labrie F,Belanger A, Dupont A, et al. Science behind total androgen blockade from gene to combination therapy [J].Clin Invest Meet, 1993,16:475-492. 被引量:1
  • 10Fritz HS. Hormonal therapy of prostate cancer//Walsh PC, Retik AB,Vaughan ED, et. eds. Campbell's Urology [ M ].Vol 4.8th ed. Philadelphia : Saunders,2002 : 3218. 被引量:1

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部